Get the Stockscreener App
2.01
2.43%
-0.05
Pre-market:
2.02
0.01
+0.50%
Fate Therapeutics Inc stock is traded at $2.01, with a volume of 2.85M.
It is down -2.43% in the last 24 hours and up +14.53% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$2.06
Open:
$2.105
24h Volume:
2.85M
Relative Volume:
1.01
Market Cap:
$234.28M
Revenue:
$6.65M
Net Income/Loss:
$-136.32M
P/E Ratio:
-1.7513
EPS:
-1.1477
Net Cash Flow:
$-112.04M
1W Performance:
+5.24%
1M Performance:
+14.53%
6M Performance:
+79.46%
1Y Performance:
+57.65%
1-Day Range:
$1.95
$2.15
1-Week Range:
$1.82
$2.1591
52-Week Range:
$0.91
$2.88
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
2.01 | 234.28M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-26 | Resumed | Jefferies | Buy |
| Oct-31-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-27-25 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Redmile director nominee awarded 87,900 Fate Therapeutics (FATE) stock options - Stock Titan
Fate Therapeutics (FATE) director granted 87,900 stock options at $2.06 - Stock Titan
Director Yuan Xu receives 87,900 Fate Therapeutics (FATE) stock options at $2.06 - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director awarded 87,900 stock options as equity pay - Stock Titan
Fate Therapeutics (FATE) director receives 87,900 stock options at $2.06 strike - Stock Titan
Fate Therapeutics (FATE) director receives 87,900 stock options award - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director receives 87,900-share stock option grant - Stock Titan
Director at Fate Therapeutics (NASDAQ: FATE) receives 87,900 stock options grant - Stock Titan
Director Laura Hamill receives 175,800 Fate Therapeutics (FATE) stock options - Stock Titan
Director Laura Hamill files initial Form 3 for FATE Therapeutics (FATE) - Stock Titan
[8-K] FATE THERAPEUTICS INC Reports Material Event - Stock Titan
Fate Therapeutics Inc Stock (US3025491025): valuation focus as clinical-stage biotech trades near lo - AD HOC NEWS
Fate Therapeutics Appoints Laura Hamill To Board Of Directors - TradingView
Fate Therapeutics appoints Laura Hamill to board of directors - Investing.com
Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo Finance
Fate Therapeutics Appoints Laura Hamill to Board of Directors - GlobeNewswire
FATE Stock Price, Quote & Chart - ChartMill
FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT - Insider Monkey
5 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
FATE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $7.00 - GuruFocus
H.C. Wainwright reiterates Fate Therapeutics stock rating on SLE data By Investing.com - Investing.com Canada
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Fate Therapeutics Advances Off-the-Shelf CAR T-Cell Therapies for Autoimmune Diseases and Cancer – Clinical Pipeline and 2026 Updates - Minichart
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline - TipRanks
Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cash - TradingView
Fate Therapeutics (NASDAQ: FATE) details FT819, FT836 data and cash runway into 2028 - Stock Titan
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting - markets.businessinsider.com
Fate Therapeutics presents autoimmune therapy data at EULAR - Investing.com
Fate Therapeutics presents autoimmune therapy data at EULAR By Investing.com - Investing.com South Africa
Small lupus trial tests off-the-shelf CAR T with same-day discharge - Stock Titan
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
LCTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Off-the-shelf FT836 shrinks tumors in colorectal cancer without conditioning chemo - Stock Titan
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting - Yahoo Finance
Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely? - Yahoo Finance
The $13 Million Company Teaching the Immune System to Hunt Cancer - Quantisnow
Fate Therapeutics Surges Over 10% as Biotech Sector Shows Signs of Life (FATE)Equity Put Call - newsline.com
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo
FATE Q1 2026 Earnings: Narrows Loss Per Share, Stock Rises on Improved Bottom LineRevenue Growth Report - newsline.com
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares By Investing.com - Investing.com India
BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Raises Target Price to $2.2 - Moomoo
Fate Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 7%Earnings Growth Forecast - newsline.com
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares - Investing.com UK
Fate Therapeutics (FATE) officer sells 25,590 shares in tax-related transaction - Stock Titan
Fate Therapeutics (FATE) CEO executes 28,946-share sell-to-cover tax sale - Stock Titan
Fate Therapeutics to present CAR T-cell data at medical conferences By Investing.com - Investing.com South Africa
Fate Therapeutics to present CAR T-cell therapy data at medical conferences - StreetInsider
Fate Therapeutics to present CAR T-cell data at medical conferences - Investing.com
Fate Therapeutics Announces Presentations at 2026 ASCO and - GlobeNewswire
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):